{"url_path":"/sec/rvph/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1742927/0001437749-26-016762-index.html","accession_number":"0001437749-26-016762","cik":"0001742927","ticker":"RVPH","issuer_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1742927/0001437749-26-016762-index.html","primary_entity_key":"0001742927","primary_entity_name":"REVIVA PHARMACEUTICALS HOLDINGS, INC."},"word_count":696,"has_tables":true,"body_markdown":"rvph20260331_10q.htm\n\nQ1\n2026\n--12-31\nfalse\n0001742927\nfalse\nfalse\nfalse\nfalse\n1\n1\n12\n0\n0\n12\n5\n1\n1\n0.0001\n3\n1\nNASDAQ\n\n00017429272026-01-012026-03-31\nthunderdome:item\n00017429272025-07-012025-09-30\nxbrli:pure\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-03-31\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-03-31\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-03-31\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-03-31\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-03-31\n0001742927rvph:PrivateWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-03-31\nxbrli:shares\n0001742927rvph:PrivateWarrantsMember2025-12-142025-12-14\niso4217:USD\n00017429272025-03-31\n00017429272026-03-31\n00017429272025-01-012025-03-31\n00017429272024-12-31\n00017429272025-12-31\n0001742927us-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2025-12-31\n0001742927us-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2026-03-31\n0001742927rvph:CorporateOfficeLease2Member2026-01-012026-03-31\nutr:M\n0001742927rvph:CorporateOfficeLeaseMember2026-01-01\n0001742927rvph:CorporateOfficeLease2Member2026-03-31\n0001742927rvph:GeneralAndAdministrativeExpensesMember2025-01-012025-03-31\n0001742927rvph:GeneralAndAdministrativeExpensesMember2026-01-012026-03-31\n0001742927rvph:ResearchAndDevelopmentExpensesMember2025-01-012025-03-31\n0001742927rvph:ResearchAndDevelopmentExpensesMember2026-01-012026-03-31\n0001742927us-gaap:EmployeeStockOptionMember2026-03-31\nutr:Y\n0001742927us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\niso4217:USDxbrli:shares\n0001742927us-gaap:EmployeeStockOptionMember2024-12-31\n0001742927us-gaap:EmployeeStockOptionMember2024-01-012024-12-31\n0001742927us-gaap:EmployeeStockOptionMember2023-12-31\n0001742927us-gaap:EmployeeStockOptionMember2023-01-012023-12-31\n0001742927srt:MaximumMember2025-01-012025-03-31\n0001742927srt:MinimumMember2026-01-012026-03-31\n0001742927rvph:EquityIncentivePlan2020Member2025-01-012025-01-01\n0001742927rvph:EquityIncentivePlan2020Member2025-01-012025-12-31\n0001742927rvph:May2025ATMSalesAgreementMember2026-01-012026-03-31\n0001742927rvph:May2025ATMSalesAgreementMember2025-05-30\n0001742927rvph:EquityIncentivePlan2020Member2026-03-31\n0001742927rvph:TheMarch2026PublicOfferingMember2026-03-202026-03-20\n00017429272025-12-18\n00017429272025-12-17\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2025-06-26\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputExercisePriceMember2025-06-26\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputSharePriceMember2025-06-26\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2025-06-26\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputExpectedTermMember2025-06-26\n0001742927rvph:June2025SeriesDCommonWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-06-26\n0001742927rvph:June2025SeriesCCommonWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2025-06-26\n0001742927rvph:March2026PrefundedWarrantsMember2026-03-20\n0001742927rvph:SeriesHWarrantsMember2026-03-20\n0001742927rvph:SeriesGWarrantsMember2026-03-20\n0001742927rvph:TheMarch2026PublicOfferingMember2026-03-202026-03-20\n0001742927rvph:March2026CommonStockWarrantsMember2026-03-20\n0001742927rvph:March2026SeriesHWarrantsMember2026-03-31\n0001742927rvph:March2026SeriesHWarrantsMember2026-01-012026-03-31\n0001742927rvph:March2026SeriesHWarrantsMember2025-12-31\n0001742927rvph:March2026SeriesGWarrantsMember2026-03-31\n0001742927rvph:March2026SeriesGWarrantsMember2026-01-012026-03-31\n0001742927rvph:March2026SeriesGWarrantsMember2025-12-31\n0001742927rvph:March2026PrefundedWarrantsMember2026-03-31\n0001742927rvph:March2026PrefundedWarrantsMember2026-01-012026-03-31\n0001742927rvph:March2026PrefundedWarrantsMember2025-12-31\n0001742927rvph:September2025SeriesFCommonWarrantsMember2026-03-31\n0001742927rvph:September2025SeriesFCommonWarrantsMember2026-01-012026-03-31\n0001742927rvph:September2025SeriesFCommonWarrantsMember2025-12-31\n0001742927rvph:September2025SeriesECommonWarrantsMember2026-03-31\n0001742927rvph:September2025SeriesECommonWarrantsMember2026-01-012026-03-31\n0001742927rvph:September2025SeriesECommonWarrantsMember2025-12-31\n0001742927rvph:June2025SeriesDCommonWarrantsMember2026-03-31\n0001742927rvph:June2025SeriesDCommonWarrantsMember2026-01-012026-03-31\n0001742927rvph:June2025SeriesDCommonWarrantsMember2025-12-31\n0001742927rvph:June2025SeriesCCommonWarrantsMember2026-03-31\n0001742927rvph:June2025SeriesCCommonWarrantsMember2026-01-012026-03-31\n0001742927rvph:June2025SeriesCCommonWarrantsMember2025-12-31\n0001742927rvph:TheDecember2024SeriesBCommonWarrantsMember2026-03-31\n0001742927rvph:TheDecember2024SeriesBCommonWarrantsMember2026-01-012026-03-31\n0001742927rvph:TheDecember2024SeriesBCommonWarrantsMember2025-12-31\n0001742927rvph:TheAugust2024UnderwriterWarrantsMember2026-03-31\n0001742927rvph:TheAugust2024UnderwriterWarrantsMember2026-01-012026-03-31\n0001742927rvph:TheAugust2024UnderwriterWarrantsMember2025-12-31\n0001742927rvph:August2024CommonStockWarrantsMember2026-03-31\n0001742927rvph:August2024CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:August2024CommonStockWarrantsMember2025-12-31\n0001742927rvph:May2024CommonStockWarrantsMember2026-03-31\n0001742927rvph:May2024CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:May2024CommonStockWarrantsMember2025-12-31\n0001742927rvph:November2023PreFundedWarrantsMember2026-03-31\n0001742927rvph:November2023PreFundedWarrantsMember2026-01-012026-03-31\n0001742927rvph:November2023PreFundedWarrantsMember2025-12-31\n0001742927rvph:AugustAmendedNovember2023CommonStockWarrantsMember2026-03-31\n0001742927rvph:AugustAmendedNovember2023CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:AugustAmendedNovember2023CommonStockWarrantsMember2025-12-31\n0001742927rvph:MayAmendedNovember2023CommonStockWarrantsMember2026-03-31\n0001742927rvph:MayAmendedNovember2023CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:MayAmendedNovember2023CommonStockWarrantsMember2025-12-31\n0001742927rvph:November2023CommonStockWarrantsPostAmendmentMember2026-03-31\n0001742927rvph:November2023CommonStockWarrantsPostAmendmentMember2026-01-012026-03-31\n0001742927rvph:November2023CommonStockWarrantsPostAmendmentMember2025-12-31\n0001742927rvph:September2022CommonStockWarrantsMember2026-03-31\n0001742927rvph:September2022CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:September2022CommonStockWarrantsMember2025-12-31\n0001742927rvph:September2022PrivatePreFundedWarrantsMember2026-03-31\n0001742927rvph:September2022PrivatePreFundedWarrantsMember2026-01-012026-03-31\n0001742927rvph:September2022PrivatePreFundedWarrantsMember2025-12-31\n0001742927rvph:AmendedJune2021CommonStockWarrantsMember2026-03-31\n0001742927rvph:AmendedJune2021CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:AmendedJune2021CommonStockWarrantsMember2025-12-31\n0001742927rvph:June2021CommonStockWarrantsPostAmendmentMember2026-03-31\n0001742927rvph:June2021CommonStockWarrantsPostAmendmentMember2026-01-012026-03-31\n0001742927rvph:June2021CommonStockWarrantsPostAmendmentMember2025-12-31\n0001742927rvph:PrefundedWarrantsMember2025-03-31\n0001742927rvph:PrefundedWarrantsWithExercisePrice0001Member2026-03-31\n0001742927rvph:PrefundedWarrantsWithExercisePrice0002Member2026-03-31\n0001742927rvph:PrefundedWarrantsMember2026-03-31\n0001742927us-gaap:WarrantMember2025-01-012025-03-31\n0001742927us-gaap:WarrantMember2026-01-012026-03-31\n0001742927us-gaap:EmployeeStockOptionMember2025-01-012025-03-31\n0001742927us-gaap:EmployeeStockOptionMember2026-01-012026-03-31\n0001742927rvph:FinancingForLiabilityInsurancePolicyPremiumsMember2025-01-012025-12-31\n0001742927rvph:FinancingForLiabilityInsurancePolicyPremiumsMember2025-12-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMemberrvph:VendorThreeMember2025-01-012025-03-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMemberrvph:VendorTwoMember2025-01-012025-03-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMemberrvph:VendorOneMember2025-01-012025-03-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMember2025-01-012025-03-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMemberrvph:VendorOneMember2026-01-012026-03-31\n0001742927rvph:ResearchAndDevelopmentCostsMemberus-gaap:SupplierConcentrationRiskMember2026-01-012026-03-31\n0001742927rvph:ReverseStockSplitMember2026-03-092026-03-09\n0001742927rvph:PrefundedWarrantsMember2025-01-012025-03-31\n0001742927rvph:PrefundedWarrantsMember2026-01-012026-03-31\n0001742927rvph:CommonStockWarrantsMember2025-01-012025-03-31\n0001742927rvph:CommonStockWarrantsMember2026-01-012026-03-31\n0001742927rvph:TheMarketOfferingAgreementAtmAgreementMember2025-01-012025-03-31\n0001742927rvph:TheMarketOfferingAgreementAtmAgreementMember2026-01-012026-03-31\n0001742927us-gaap:RetainedEarningsMember2025-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2025-03-31\n0001742927us-gaap:CommonStockMember2025-03-31\n0001742927rvph:May2025ATMSalesAgreementMember2025-01-012025-03-31\n0001742927us-gaap:RetainedEarningsMember2025-01-012025-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2025-01-012025-03-31\n0001742927us-gaap:CommonStockMember2025-01-012025-03-31\n0001742927us-gaap:RetainedEarningsMember2024-12-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2024-12-31\n0001742927us-gaap:CommonStockMember2024-12-31\n0001742927us-gaap:RetainedEarningsMember2026-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2026-03-31\n0001742927us-gaap:CommonStockMember2026-03-31\n0001742927us-gaap:RetainedEarningsMember2026-01-012026-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2026-01-012026-03-31\n0001742927us-gaap:CommonStockMember2026-01-012026-03-31\n0001742927rvph:PublicOfferingMember2026-01-012026-03-31\n0001742927us-gaap:RetainedEarningsMemberrvph:PublicOfferingMember2026-01-012026-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMemberrvph:PublicOfferingMember2026-01-012026-03-31\n0001742927us-gaap:CommonStockMemberrvph:PublicOfferingMember2026-01-012026-03-31\n0001742927us-gaap:RetainedEarningsMemberrvph:TheMarketOfferingAgreementAtmAgreementMember2026-01-012026-03-31\n0001742927us-gaap:AdditionalPaidInCapitalMemberrvph:TheMarketOfferingAgreementAtmAgreementMember2026-01-012026-03-31\n0001742927us-gaap:CommonStockMemberrvph:TheMarketOfferingAgreementAtmAgreementMember2026-01-012026-03-31\n0001742927us-gaap:RetainedEarningsMember2025-12-31\n0001742927us-gaap:AdditionalPaidInCapitalMember2025-12-31\n0001742927us-gaap:CommonStockMember2025-12-31\n00017429272026-05-13\n\n0001742927rvph:TheJune2025WarrantsMember2026-01-012026-03-31\n\n \n\n** UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n**FORM 10-Q**\n\n*(Mark One)*\n\n☒\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the quarterly period ended March 31, 2026**\n\n \n\n**or**\n\n \n\n☐\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n**For the transition period from**    ____  **to ____**\n\n \n\n**Commission file number: 001-38634**\n\n**Reviva Pharmaceuticals Holdings, Inc.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Delaware**\n\n \n\n**85-4306526**\n\n(State or other jurisdiction of\n\n \n\n(I.R.S. Employer Identification No.)\n\nincorporation or organization)\n\n \n \n\n \n \n \n\n**10080 N. Wolfe Road, Suite SW3-200**\n\n \n \n\n**Cupertino, CA**\n\n \n\n**95014**\n\n(Address of principal executive offices)\n\n \n\n(Zip Code)\n\n \n\n**(408) 501-8881**\n\n(Registrant’s telephone number, including area code)\n\n \n\n**Not applicable**\n\n(Former name, former address and former fiscal year,\n\nif changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title of each class**\n\n**Trading Symbol(s)**\n\n**Name of each exchange on which registered**\n\nCommon Stock, par value $0.0001 per share\n\nRVPH\n\nThe Nasdaq Capital Market*\n\n \n\n*Trading of the registrant’s common stock on Nasdaq will be suspended on May 14, 2026. The registrant’s common stock will be quoted on the OTCQB Venture Market operated by OTC Markets Group Inc. under the symbol “RVPH”.\n\n \n\n \n\nIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.\n\n \n\nLarge accelerated filer ☐\n\nAccelerated filer ☐\n\n \n \n\nNon-accelerated filer ☒\n\nSmaller reporting company ☒\n\n \n\nEmerging growth company ☐\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ No ☒\n\n \n\nAs of May 13, 2026 the number of outstanding shares of the registrant’s common stock, par value $0.0001 per share, was 13,110,377.\n\n \n\n \n\n \n\n \n\n  \n\n \n\n**REVIVA PHARMACEUTICALS HOLDINGS, INC.**\n\n**FORM 10-Q TABLE OF CONTENTS**\n\n \n\n \n \n\n**Page**\n\n**Part** **I**\n\n**Financial Information**"}